PRSS3/mesotrypsin in prostate cancer progression: Implications for translational medicine

Asian Journal of Andrology

Volumn 15, Issue 4, 2013, Pages 439-440

  Radisky, Evette S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTRYPSIN; MESOTRYPSIN INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MOTILITY; GENE SILENCING; HUMAN; METASTASIS; PROSTATE CANCER; TUMOR INVASION;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; TRYPSIN; TRYPSIN INHIBITORS;

EID: 84880113020     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.14     Document Type: Article

References (14)

1. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
2. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ et al. A tissue biomarker panel predicting systemic progression after PSA recurrence postdefinitive prostate cancer therapy. PLoS ONE 2008; 3: e2318.
3. Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castrationresistant prostate cancer patients. Clin Cancer Res 2011; 17: 3867-75.
4. Kelloff GJ, Sigman CC. Cancer biomarkers: selectin. The right drug fo. The right patient. Nat Rev Drug Discov 2012; 11: 201-14.
5. Liotta LA, Petricoin EF 3rd. -Omics and cancer biomarkers: link t. The biological truth or bea. The consequences. Cancer Epidemiol Biomarkers Prev 2012; 21: 1229-35.
6. Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC et al. PRSS3iMesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res 2012; 10: 1555-66.
7. Lazebnik Y. What ar. The hallmarks of cancer? Nat Rev Cancer 2010; 10: 232-3.
8. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
9. Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007; 8: 279-87.
10. Radisky ES, Radisky DC. Matrix metalloproteinaseinduced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 201-12.
11. Jiang G, Cao F, Ren G, Gao D, Bhakta V et al. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut 2010; 59: 1535-44.
12. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P29 residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J 2011; 440: 95-105.
13. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R et al. The role of SPINK1 in ETS rearrangementnegative prostate cancers. Cancer Cell 2008; 13: 519-28.
14. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3: 72ra17.